X
(All Fields are required)
Other Resource

Advancing Integrity in Medical Education


A new national initiative to improve conflict-of-interest policies at academic medical centers


The challenge

In 2012, the drug industry spent more than $27 billion marketing medicines directly to doctors.1 Gifts and payments from industry to doctors can affect the choices they make when they treat patients, and the usual result is the prescription of new, high-priced, brand-name medications rather than well-established generic drugs that have longer track records of safety.2,3,4

A solution based in education

The Pew Charitable Trusts is working to decrease the influence of pharmaceutical marketing on doctors’ practices. With a three-year grant from the Attorney General Consumer and Prescriber Education Grant Program, Pew is collaborating with the American Medical Student Association, Community Catalyst, and the National Physicians Alliance to improve conflict-of-interest policies within the 158 medical schools and 400 major teaching hospitals in the United States. Together, we are developing a set of best-practice standards, determining whether academic medical centers have adopted these practices, and providing technical assistance to these institutions. Our goal is that 75 percent of academic medical centers will implement strong conflict-of-interest policies by 2014.

 

pharmfree-redo-250
PharmFree Scorecard 2013

The following resources and opportunities are available:

  • Expert task force on medical conflicts of interest: A team of leaders in the medical institutions that will create policy recommendations for medical schools and teaching hospitals, which will appear in various publications.
  • National grand rounds: Events with expert speakers who share their experiences on conflict-of-interest topics.
    (Lectures are Web-archived, and free continuing medical education credits are available.)
  • Tool kits: Customizable materials that can help institutions improve their conflict-of-interest policies.
  • Micro-grants: Funding opportunities for medical students to implement conflict-of-interest projects on their campuses.

Who we are

Pew’s prescription project is the lead organization coordinating the activities of the Partnership to Advance Conflict-Free Medical Education. The prescription project seeks to ensure transparency in physician-industry relationships and promotes policies to reduce or manage conflicts of interest that could affect patient care. 

Contact:

Sallyann Bergh
The Pew Charitable Trusts
202-540-6783
sbergh@pewtrusts.org

The American Medical Student Association is a student-governed national organization committed to representing the concerns of physicians-in-training. Since 2007, the association’s annual scorecard has tracked conflict-of-interest policies in medical schools, using a letter grade to evaluate their adequacy. The scorecard has been an effective tool for encouraging schools to adopt model policies.

Community Catalyst is a national nonprofit advocacy organization whose first priority is high-quality, affordable health care for all. It has worked closely with Pew and the American Medical Student Association on improving conflict-of-interest policies in medical settings nationwide.

The National Physicians Alliance is a nonprofit membership and advocacy organization that represents physicians across medical specialties who share a commitment to professional integrity and health justice. Its “Unbranded Doctor” campaign provides guidance and tools for health-care practitioners who value practicing medicine free from undue influence from the pharmaceutical industry.

This partnership and related materials were made possible by a grant from the state Attorney General Consumer and Prescriber Education Grant Program, which is funded by the multistate settlement of consumer fraud claims regarding the marketing of the prescription drug Neurontin.


References

1 Cegedim Strategic Data, “2012 U.S. Pharmaceutical Company Promotion Spending,” accessed April 18, 2013, skainfo.com/health_care_market_reports/2012_promotional_spending.pdf.

2 Erik G. Campbell, Geneveive Pham-Kanter, Christine Vogeli, and Lisa I. Iezzoni, “Physician Acquiescence to Patient Demands for Brand-Name Drugs: Results of a National Survey of Physicians,” JAMA Internal Medicine 173 (2013): 237-239.

3 Marissa King, Connor Essick, Peter Bearman, and Joseph S. Ross, “Medical School Gift Restriction Policies and Physician Prescribing of Newly Marketed Psychotropic Medications: Difference-in-Differences Analysis,” British Medical Journal 346 (2013): 264.

4 Geoffery K. Spurling, Peter R. Mansfield, Brett D. Montgomery, et al., “Information From Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians’ Prescribing: A Systematic Review,” PLoS Medicine 7 (2010): e1000352. 

Date added:
May 21, 2013

Related Resources

''Already Feeling the Heat''

Media Coverage

"The legislation requiring public disclosure of the financial relationships between healthcare vendors and physicians has been widely discussed in policy circles for years. Critics claimed payments for speaking, consulting, research or even the small trinkets and meals delivered during routine sales calls unduly influenced physician choices and inflated healthcare costs. To combat those effects, Congress required public reporting of those payments in a publicly accessible database. The legislation, labeled the Physician Payment Sunshine Act, was included in the 2010 healthcare reform law."

More

Letter from Pew to CMS Regarding Physician Payments Sunshine Act

Issue Brief

Prescription project director Danny Carlat identifies issues with the Physician Payments Sunshine Act requiring further clarification and guidance. Addressing those would ensure that manufacturers can appropriately implement the final rule, and enable consumers to benefit from transparency reports published by the Centers for Medicare & Medicaid Services.

More

Pew Comments on Centers for Medicaid and Medicare Services' Information Collection Activities Draft Guidance

Issue Brief

The Pew Charitable Trusts appreciates this opportunity to submit comments to CMS's "Information Collection Activities" draft guidance. We suggest that both the research and non-research payment templates be modified in order to make it easier for consumers to identify which drugs, devices, biologicals, or medical supplies are associated with particular transfers of value.

More

One Step Closer to Medical Transparency: Pew's Analysis of the Final Rule for the Physician Payments Sunshine Act

Other Resource
On Feb. 1, 2013, the Centers for Medicare & Medicaid Services published the final rule guiding implementation of the Physician Payments Sunshine Act, which Congress passed as part of the Affordable Care Act in March 2010 to increase transparency in the relationships between physicians and drug and medical device makers. Here are some of the highlights. More

''Finding Out Who Pays Your Doctor''

Opinion

"The Obama administration issued a new rule this month that requires the makers of prescription drugs and other medical products to disclose what they pay doctors for various purposes, like consulting or speaking on behalf of the manufacturer. This overdue rule adds much-needed weight to previous, more limited disclosure requirements."

More

Pew Commends Strong Transparency Rule for Physician-Industry Relationships

Press Release

Allan Coukell, director of medical programs for The Pew Charitable Trusts, issued the following statement in response to the Centers for Medicare & Medicaid Services' final rule for implementing the Physician Payments Sunshine Act, which will bring transparency to the financial relationships between physicians and drug and medical device companies.

More

Persuading the Prescribers: Pharmaceutical Industry Marketing and its Influence on Physicians and Patients

Other Resource

In 2011, the pharmaceutical industry spent nearly $29 billion on drug promotion — more than $25 billion on marketing directly to physicians and almost $4 billion on advertising directly to consumers (mainly through television commercials). This multi-pronged approach is designed to promote its products by influencing doctors’ prescribing practices.

 

More

''One-Stop Shopping Proposed For Conflict Disclosure''

Media Coverage

"Harmonizing conflict-of-interest standards will depend on the Centers for Medicare & Medicaid Services moving forward to implement the federal Sunshine law, which is now more than a year behind schedule. Industry, consumers and academic stakeholders are all waiting on CMS to issue a final rule."

More

''Is Psychiatry Committing 'Professional Suicide'?''

Media Coverage

During a session at the American Psychiatric Association's annual meeting on conflicts of interest, experts delved into the link between psychiatry and the pharmaceutical industry. While several speakers at the session pointed out that other specialties are similarly entangled with industry, "everyone does it" is generally not a valid defense where conflicts of interest are concerned.

More

Written Statement of Record Regarding the Sunshine Act by Dr. Daniel J. Carlat of the Pew Health Group

Issue Brief

Dr. Daniel Carlat, Director of the Pew Prescription Project, appeared before the U.S. Senate Special Committee on Aging to testify about the importance of implementing the Physician Payments Sunshine Act as quickly as possible.

More

''Disclosure can address doctors' conflicts of interest''

Opinion

Pew Prescription Project Director Daniel Carlat opines in the Philadelphia Inquirer: "Monetary relationships among doctors and drug and device companies are not inherently bad; in fact, they are crucial for advancing medical research and patient care. Yet they can also skew prescribing practices and research results. That's why transparency and education are such an elegant solution: They allow these often important relationships to exist, but only on the condition that other professionals and patients are fully informed about them."

More

''FDA Fee Reauthorization a Prescription for Debate''

Media Coverage

"Every five years, lawmakers, lobbyists, patient groups and agency regulators line up to take their shot at changing how things get done at the Food and Drug Administration."

More

Joint Comments with Medtronic to CMS on Sunshine Implementation

Issue Brief

The Pew Charitable Trusts “Pew” and Medtronic, Inc. are pleased to jointly comment on the Department of Health and Human Services, Centers for Medicare & Medicaid Services proposed rule implementing Section 6002 of the Affordable Care Act.

More

Comments to CMS on Sunshine Implementation

Issue Brief
Pew’s main goals in commenting on the proposed rule are to ensure timely implementation and to promote the interest of full transparency by ensuring that data is collected, reported, and published in the most complete, consistent and accurate manner possible. More

Expert Profile: Allan Coukell

Video

Allan Coukell, Deputy Director, Medical Programs

More